{"success":true,"data":{"pressRelease":{"id":"129921","rtpr_id":"nNFC6Xqqmr","ticker":"NGMD","exchange":"","all_tickers":["NGMD"],"title":"NuGen Announces Filing of Corrective Disclosure Pursuant to OSC Review","author":"Newsfile Corp","published_at":"2026-08-27T21:30:11.544Z","article_body":"Toronto, Ontario--(Newsfile Corp. - August 27, 2026) - NuGen Medical Devices\nInc. (TSXV: NGMD) (\"NuGen\" or the \"Company\") announces that further to the\nreview by the Ontario Securities Commission (\"OSC\") of the Company's\ncontinuous disclosure, the Company has made corrective disclosure with respect\nto the following:\n* the Company has included in its recently filed management information\ncircular dated August 17, 2026 (the \"Circular\") the executive compensation\ndisclosure for the year ended December 31, 2025, required pursuant to NI\n51-102 - Continuous Disclosure Obligations;\n* the Company has included in the Circular the corporate governance disclosure\nrequired pursuant to form NI 58-102F2 - Corporate Governance Disclosure\n(Venture Issuers) and the audit committee disclosure required pursuant to form\n52-110F2 - Disclosure by Venture Issuers.\nThe Circular has been filed on the Company's SEDAR+ profile at\nwww.sedarplus.ca.\n\nCorrective disclosure was requested by OSC staff in connection with the\nCompany's continuous disclosure. The Company has provided explanations to OSC\nstaff requests and has also included the requested information in the\nCircular.\n\nAs a result of having to provide such corrective disclosure, the Company will\nbe placed on the public list of Refilling and Errors (the \"List\") in\naccordance with OSC Staff Notice 51-711 and will remain on the List for a\nperiod of three years from the date of refiling the corrective disclosure.\n\nAbout NuGen Medical Devices\n\nNuGen develops needle-free devices for subcutaneous drug delivery. Its\nflagship InsuJet™ system is approved in 42 countries and is designed to\nimprove the lives of millions of people with diabetes worldwide.\n\nWebsites: insujet.com (https://api.newsfilecorp.com/redirect/YEyAaSxELJ) |\ninsujet.fr (https://api.newsfilecorp.com/redirect/0pbBQu5pqr) | nugenmd.com\n(https://api.newsfilecorp.com/redirect/RY2xaIw5Pk)\nLinkedIn: https://www.linkedin.com/company/nugen-medical-devices\nInvestor Relations: IR@nugenmd.com\n\nFor further information, please contact:\n\nAjay Mishra,\nChief Financial Officer\n+1-833-867-5557\nir@nugenmd.com\n\nNotice Regarding Forward-Looking Information:\n\nNeither TSXV nor its Regulation Services Provider (as that term is defined in\nthe policies of the TSXV) accept responsibility for the adequacy or accuracy\nof this release.\n\nThis news release contains \"forward-looking information\" and \"forward-looking\nstatements\" (collectively, \"forward-looking statements\") within the meaning of\nthe applicable Canadian securities legislation. All statements, other than\nstatements of historical fact, are forward-looking statements and are based on\nexpectations, estimates and projections as at the date of this news release.\nAny statement that involves discussions with respect to predictions,\nexpectations, beliefs, plans, projections, objectives, assumptions, future\nevents or performance (often but not always using phrases such as \"expects\",\nor \"does not expect\", \"is expected\", \"anticipates\" or \"does not anticipate\",\n\"plans\", \"budget\", \"scheduled\", \"forecasts\", \"estimates\", \"believes\" or\n\"intends\" or variations of such words and phrases or stating that certain\nactions, events or results \"may\" or \"could\", \"would\", \"might\" or \"will\" be\ntaken to occur or be achieved) are not statements of historical fact and may\nbe forward-looking statements. These forward-looking statements are subject to\na variety of risks and uncertainties and other factors that could cause actual\nevents or results to differ materially from those projected in the\nforward-looking information. The forward-looking information contained herein\nis given as of the date hereof and the Company assumes no responsibility to\nupdate or revise such information to reflect new events or circumstances,\nexcept as required by law.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/311906","article_body_html":"","raw_payload":{"data":{"id":"nNFC6Xqqmr","title":"NuGen Announces Filing of Corrective Disclosure Pursuant to OSC Review","author":"Newsfile Corp","ticker":"NGMD","created":"2026-08-27T21:30:11.544Z","tickers":["NGMD"],"exchange":"","article_body":"Toronto, Ontario--(Newsfile Corp. - August 27, 2026) - NuGen Medical Devices\nInc. (TSXV: NGMD) (\"NuGen\" or the \"Company\") announces that further to the\nreview by the Ontario Securities Commission (\"OSC\") of the Company's\ncontinuous disclosure, the Company has made corrective disclosure with respect\nto the following:\n* the Company has included in its recently filed management information\ncircular dated August 17, 2026 (the \"Circular\") the executive compensation\ndisclosure for the year ended December 31, 2025, required pursuant to NI\n51-102 - Continuous Disclosure Obligations;\n* the Company has included in the Circular the corporate governance disclosure\nrequired pursuant to form NI 58-102F2 - Corporate Governance Disclosure\n(Venture Issuers) and the audit committee disclosure required pursuant to form\n52-110F2 - Disclosure by Venture Issuers.\nThe Circular has been filed on the Company's SEDAR+ profile at\nwww.sedarplus.ca.\n\nCorrective disclosure was requested by OSC staff in connection with the\nCompany's continuous disclosure. The Company has provided explanations to OSC\nstaff requests and has also included the requested information in the\nCircular.\n\nAs a result of having to provide such corrective disclosure, the Company will\nbe placed on the public list of Refilling and Errors (the \"List\") in\naccordance with OSC Staff Notice 51-711 and will remain on the List for a\nperiod of three years from the date of refiling the corrective disclosure.\n\nAbout NuGen Medical Devices\n\nNuGen develops needle-free devices for subcutaneous drug delivery. Its\nflagship InsuJet™ system is approved in 42 countries and is designed to\nimprove the lives of millions of people with diabetes worldwide.\n\nWebsites: insujet.com (https://api.newsfilecorp.com/redirect/YEyAaSxELJ) |\ninsujet.fr (https://api.newsfilecorp.com/redirect/0pbBQu5pqr) | nugenmd.com\n(https://api.newsfilecorp.com/redirect/RY2xaIw5Pk)\nLinkedIn: https://www.linkedin.com/company/nugen-medical-devices\nInvestor Relations: IR@nugenmd.com\n\nFor further information, please contact:\n\nAjay Mishra,\nChief Financial Officer\n+1-833-867-5557\nir@nugenmd.com\n\nNotice Regarding Forward-Looking Information:\n\nNeither TSXV nor its Regulation Services Provider (as that term is defined in\nthe policies of the TSXV) accept responsibility for the adequacy or accuracy\nof this release.\n\nThis news release contains \"forward-looking information\" and \"forward-looking\nstatements\" (collectively, \"forward-looking statements\") within the meaning of\nthe applicable Canadian securities legislation. All statements, other than\nstatements of historical fact, are forward-looking statements and are based on\nexpectations, estimates and projections as at the date of this news release.\nAny statement that involves discussions with respect to predictions,\nexpectations, beliefs, plans, projections, objectives, assumptions, future\nevents or performance (often but not always using phrases such as \"expects\",\nor \"does not expect\", \"is expected\", \"anticipates\" or \"does not anticipate\",\n\"plans\", \"budget\", \"scheduled\", \"forecasts\", \"estimates\", \"believes\" or\n\"intends\" or variations of such words and phrases or stating that certain\nactions, events or results \"may\" or \"could\", \"would\", \"might\" or \"will\" be\ntaken to occur or be achieved) are not statements of historical fact and may\nbe forward-looking statements. These forward-looking statements are subject to\na variety of risks and uncertainties and other factors that could cause actual\nevents or results to differ materially from those projected in the\nforward-looking information. The forward-looking information contained herein\nis given as of the date hereof and the Company assumes no responsibility to\nupdate or revise such information to reflect new events or circumstances,\nexcept as required by law.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/311906"},"type":"article","timestamp":"2026-08-27T21:30:11.616432613Z","server_sent_at_ms":1787866211616},"received_at":"2026-08-27T21:30:11.679Z","source_url":"https://www.newsfilecorp.com/release/311906"},"analysis":{"id":"118833","press_release_id":"129921","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["Company placed on OSC Refiling and Errors list for three years","Corrective disclosure required by OSC staff for missing exec comp and governance info"],"eventType":"regulatory","narrative":"NuGen Medical Devices filed a corrective disclosure for its management information circular following a review by the Ontario Securities Commission regarding missing executive compensation and corporate governance details.\n\nThe remediation includes executive compensation data for the year ended December 31, 2025, and required audit committee disclosures that were previously omitted.\n\nAs a result of these deficiencies, NuGen will be placed on the OSC's public list of Refiling and Errors for a period of three years.","sentiment":"bearish","agentHooks":{"shouldPost":false,"suggestedAngle":"Governance lapse results in three-year OSC listing."},"keyFigures":{"customDimensions":{"compensation_year":2025,"list_duration_years":"three"}},"quotedText":"","namedEntities":{"people":[{"name":"Ajay Mishra","role":"Chief Financial Officer"}],"products":["InsuJet"],"companies":[{"name":"NuGen Medical Devices Inc.","ticker":"NGMD"},{"name":"Ontario Securities Commission","relationship":"regulator"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"The company was forced to make corrective disclosure regarding executive compensation and governance by the OSC and will be placed on the Refiling and Errors list for three years, signaling a failure in compliance processes."},"tickerRelevance":{"others":[],"primary":"NGMD"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"regulatory_non_compliance","sectorWeight":"health_care"}},"event_type":"regulatory","event_type_secondary":null,"sentiment":"bearish","material_impact_score":3,"narrative":"NuGen Medical Devices filed a corrective disclosure for its management information circular following a review by the Ontario Securities Commission regarding missing executive compensation and corporate governance details.\n\nThe remediation includes executive compensation data for the year ended December 31, 2025, and required audit committee disclosures that were previously omitted.\n\nAs a result of these deficiencies, NuGen will be placed on the OSC's public list of Refiling and Errors for a period of three years.","key_figures":{"customDimensions":{"compensation_year":2025,"list_duration_years":"three"}},"named_entities":{"people":[{"name":"Ajay Mishra","role":"Chief Financial Officer"}],"products":["InsuJet"],"companies":[{"name":"NuGen Medical Devices Inc.","ticker":"NGMD"},{"name":"Ontario Securities Commission","relationship":"regulator"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-27T21:33:17.199Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"regulatory_non_compliance","sectorWeight":"health_care"}},"durationMs":115488,"modelName":"glm-4.7"}}